文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒特殊人群用药

成人肾移植受者霉酚酸暴露-毒性关系:定性批判性综述

Exposure-Toxicity Relationships of Mycophenolic Acid in Adult Kidney Transplant Patients.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

本文为定性批判性综述,纳入28篇成人肾移植受者中同时报告霉酚酸AUC与毒性数据的同行评议论文,评估霉酚酸暴露与不良反应的关系。结果发现胃肠道、感染及血液学毒性的暴露阈值证据不一致,少数研究提示总霉酚酸AUC > 40-60 mg h/L可能相关,但尚不足以定义用于治疗药物监测的毒性阈值。

要点

  • 总霉酚酸AUC 30-60 mg h/L的治疗目标不能充分表征霉酚酸相关不良反应。
  • 胃肠道、感染和血液学毒性的暴露阈值研究结果不一致,少数研究提示>40-60 mg h/L。
  • 游离霉酚酸暴露、代谢物及临床因素对毒性表现的作用尚待明确。

核心结论

  • 目前尚不能为霉酚酸治疗药物监测定义毒性阈值,但已有信息为未来研究提供了基础。

研究设计与样本

  • 定性批判性综述,纳入28篇成人肾移植受者(平均研究年龄>18岁)中同时报告霉酚酸AUC与毒性数据的同行评议论文。
  • 排除儿科研 究、缺乏AUC或毒性数据、或AUC无显著变化的论文。

主要发现

  • 对霉酚酸最常见的不良事件(胃肠道、感染和血液学),已发表的研究结果不一致。
  • 少数研究提示总霉酚酸AUC > 40-60 mg h/L可能是有前景的暴露阈值。
  • 游离霉酚酸暴露、霉酚酸代谢物或影响毒性表现的临床因素的作用仍待阐明。

关键数值与推荐

  • 成人肾移植受者中已建立的总霉酚酸AUC治疗目标为30-60 mg h/L。
  • 少数研究提示总霉酚酸AUC > 40-60 mg h/L可能与毒性相关。

临床怎么用

  • 临床不应仅依据30-60 mg h/L的治疗目标来预判霉酚酸相关不良反应。
  • 当前证据尚不支持用霉酚酸AUC毒性阈值指导治疗药物监测。

局限性

  • 纳入研究对胃肠道、感染和血液学毒性的暴露阈值结果不一致。
  • 游离霉酚酸暴露、代谢物及临床因素对毒性的影响尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mycophenolic acid is commonly prescribed in adult kidney transplant recipients for preventing graft rejection. A therapeutic target for total mycophenolic acid area under the concentration-time curve (30-60 mg h/L) has been established in adult kidney transplant recipients and widely referenced today. However, this specific target range does not adequately characterize mycophenolic acid-associated adverse effects. The primary objective of this qualitative and critical review was to characterize the exposure-toxicity relationships of mycophenolic acid in an attempt to determine whether exposure thresholds can be identified. The secondary objective was to determine the associations of clinical variables with specific adverse effects. The inclusion criteria consisted of all peer-reviewed papers in adult kidney transplant subjects (average study age > 18 years) with both exposure (area under the concentration-time curve) and toxicity data. The exclusion criteria were papers involving the pediatric population, studies lacking either area under the concentration-time curve or toxicity data, or studies with no apparent reported variations in area under the concentration-time curves. Of the 28 papers identified, inconsistent findings have been reported for the most frequently characterized adverse events of mycophenolic acid (gastrointestinal, infectious, and hematological), while promising exposure thresholds (i.e., > 40-60 mg h/L for total mycophenolic acid) have been suggested by a few studies. The roles of free mycophenolic acid exposure, mycophenolic acid metabolites, or clinical factors influencing the manifestation of the toxicities also remain to be clarified. Although it is not yet possible to define toxicity threshold(s) for the purpose of mycophenolic acid therapeutic drug monitoring, the information obtained and the limitations identified in this comprehensive literature body have provided a good foundation for future investigations.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Kiang TKL, Ensom MHH. Exposure-Toxicity Relationships of Mycophenolic Acid in Adult Kidney Transplant Patients. Clin Pharmacokinet. 2019. PMID: 31332670. doi:10.1007/s40262-019-00802-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。